Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News Archive
October 2021
-
Key ReleaseOct 26, 2021Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of SandozAd hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6% USD) Innovative Medicines grew +7% (cc, +8% USD)Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx…
-
Key ReleaseOct 26, 2021Novartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de SandozAnnonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T3 en progression de +5% (tcc¹, +6% USD)Innovative Medicines: hausse de +7% (tcc, +8% USD)Forte performance des moteurs de…
-
Key ReleaseOct 26, 2021Novartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz anAd-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz stieg im dritten Quartal um +5% (kWk¹, +6% USD) Die Division Innovative Medicines wuchs um +7% (kWk, +8% USD)Starke Performance der wichtigsten…
-
Featured NewsOct 26, 2021Novartis Financial Results – Q3 2021 -
StoryOct 26, 2021Access to Healthcare
Demystifying the science of myelodysplastic syndromes -
Key ReleaseOct 25, 2021Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancerAd hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS) in…
-
Media ReleaseOct 21, 2021Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccineAt least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia New…
-
StatementOct 21, 2021COVID-19 news feed
-
Media ReleaseOct 19, 2021Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killerInvisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (…
-
Media ReleaseOct 14, 2021Kesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosisALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there…
-
Featured NewsOct 14, 2021World Sight Day 2021 -
StoryOct 13, 2021Patient Perspectives
Restoring vision and hope to thousands in Southeast Asia